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A R T I C L E I N F O
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A B S T R A C T
Background: In phenylketonuria (PKU), weaning is considered more challenging when compared to feeding
healthy infants. The primary aim of weaning is to gradually replace natural protein from breast milk or standard
infant formula with solids containing equivalent phenylalanine (Phe). In addition, a Phe-free second stage L-
amino acid supplement is usually recommended from around 6months to replace Phe-free infant formula. Our
aim was to assess different weaning approaches used by health professionals across Europe.
Methods: A cross sectional questionnaire (survey monkey®) composed of 31 multiple and single choice questions
was sent to European colleagues caring for inherited metabolic disorders (IMD). Centres were grouped into
geographical regions for analysis.
Results: Weaning started at 17–26 weeks in 85% (n=81/95) of centres,> 26weeks in 12% (n=11/95)
and < 17weeks in 3% (n=3/95). Infant's showing an interest in solid foods, and their age, were important
determinant factors influencing weaning commencement. 51% (n=48/95) of centres introduced Phe con-
taining foods at 17–26weeks and 48% (n=46/95) at> 26weeks. First solids were mainly low Phe vegetables
(59%, n=56/95) and fruit (34%, n=32/95).
A Phe exchange system to allocate dietary Phe was used by 52% (n=49/95) of centres predominantly from
Northern and Southern Europe and 48% (n=46/95) calculated most Phe containing food sources (all centres in
Eastern Europe and the majority from Germany and Austria). Some centres used a combination of both methods.
A second stage Phe-free L-amino acid supplement containing a higher protein equivalent was introduced by
41% (n=39/95) of centres at infant age 26–36weeks (mainly from Germany, Austria, Northern and Eastern
Europe) and 37% (n=35/95) at infant age > 1y mainly from Southern Europe. 53% (n=50/95) of centres
recommended a second stage Phe-free L-amino acid supplement in a spoonable or semi-solid form.
Conclusions: Weaning strategies vary throughout European PKU centres. There is evidence to suggest that dif-
ferent infant weaning strategies may influence longer term adherence to the PKU diet or acceptance of Phe-free
L-amino acid supplements; rendering prospective long-term studies important. It is essential to identify an ef-
fective weaning strategy that reduces caregiver burden but is associated with acceptable dietary adherence and
optimal infant feeding development.
1. Background
Infants with phenylketonuria (PKU) are treated with a low pheny-
lalanine (Phe) diet supplemented with Phe-free L-amino acids (L-AA).
In early infancy, either breast milk or a standard infant formula is given
to supply Phe requirements. The volume of either milk is titrated to
individual tolerance with the remaining nutritional requirements being
provided by Phe-free L-AA infant formula [1], until the commencement
of solid introduction (weaning).
The World Health Organization (WHO) and UK Scientific Advisory
Board on Nutrition (2018) recommends that weaning should commence
from 6months of age (≈26weeks) [2] as infants are usually devel-
opmentally ready to accept solids. Alternatively, the European Society
for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)
advocates weaning from 17 to 24weeks [3]. In PKU, the definitive age
for the inauguration of weaning remains undefined as infants have al-
ready been exposed to complementary feeds in the form of Phe-free L-
AA infant formula. In addition, infants have extra stages in their feeding
development that require consideration such as the introduction of a
second stage protein substitute [4]. The weaning process may be pro-
longed as each feeding stage has to be directed by a dietitian/doctor
before changes can occur in the feeding plan.
In 1999, a multicentre study from the UK and Australia (n=13
centres) [5] reported that solids were usually introduced early (between
3 and 6months), with low Phe solids such as fruit and vegetables being
given first. Although this timing is different from weaning re-
commendations, few infants were breast fed in this study (28% of
United Kingdom patients and 41% of Australia patients). In PKU, some
infants may not be satiated with Phe-free L-AA infant formula and there
is less flexibility in adjusting breast or standard infant formula volumes
in response to appetite without adversely affecting metabolic control
(unless a protein-free formula is also administered). Although in PKU
there is no evidence to suggest that Phe-free L-AA infant formula im-
pacts on appetite, non PKU studies have established that whole protein
is more satiating than amino acid formula [6,7].
Furthermore, some infants have poor acceptance of Phe-free L-AA
infant formula and fail to drink the prescribed amounts, so they may be
hungry, leaving little choice but to proceed with the introduction of
solid foods to satisfy appetite.
It is almost 20 years since the first paper on multi-centre weaning
practices was published in PKU [5]. Differences in the timing of solid
food introduction, policies on allocation of dietary Phe, dosage and type
of protein substitute prescribed at weaning may impact on future
feeding development. Therefore, it is important to re-examine how
dietary advice on weaning differs between professionals and compare
this with weaning advice for the general population. We report the
weaning practices of health professionals working with PKU across
Europe.
2. Material and methods
A cross sectional, non-validated, survey monkey® questionnaire was
sent to European IMD (Inherited Metabolic Disorders) health profes-
sionals (dietitians/nutritionists and medical doctors) who were either
members of the ‘Society for the Study of Inborn Errors of Metabolism’
(SSIEM) or who have participated in previous European surveys as-
sessing dietary practices [8,9]. The questionnaire was composed of 31
open, single and multiple-choice questions on infant feeding in PKU
with 14 questions focused on weaning. Questions examined: weaning
age; first weaning foods; age of introduction of Phe containing foods;
method of allocating Phe into the diet; age of introduction of low
protein milk, low protein bread and ‘finger foods’; changes to protein
substitute prescription during weaning and age of introduction of
second stage protein substitute in the weaning period.
The questionnaire was written in English but linguistic support in
Portuguese, French, Spanish and Italian was provided by the first au-
thor [AP] to clarify any queries. Only one answer per centre was ac-
cepted from health professionals and participants were instructed to
answer each question according to their general clinical practice rather
than for individual patient cases. The questions were devised to
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encompass all the possible/most common practices across different
European countries. A pilot questionnaire was given to 20 dietitians
who attended an International meeting. Because of this, changes were
made to the questionnaire to improve clarity of questions if there was
ambiguity with question structure.
The questionnaire responses were analysed according to the in-
dividual centres in addition to the geographical region of responding
centres. Results were analysed in two parts: 1) early infant feeding and
2) weaning procedures. The results of the survey about early feeding
practices has already been published [10].
3. Results
3.1. Participants
Ninety-five centres from 21 European countries responded to the
questionnaire. Centres were grouped into the following geographical
regions in order to analyse the results:
• Southern Europe (n=30 centres): Portugal (n=7 centres), Italy
(n=6 centres), Spain (n=9 centres), Greece (n=2 centres) and
Turkey (n=6 centres);• Western Europe A (n=16 centres): Belgium (n=6 centres), France
(n=5 centres) and The Netherlands (n= 5 centres);• Western Europe B (n=15 centres): Germany (n=13 centres) and
Austria (n=2 centres);• Northern Europe (n=24 centres): United Kingdom (n=17 cen-
tres), Sweden (n=3 centres), Norway (n= 1 centre), Denmark
(n=1 centre), Finland (n=1 centre) and Ireland (n=1 centre);• Eastern Europe (n=10 centres): Latvia (n= 1 centre), Poland
(n=6 centres), Slovakia (n=1 centre), Hungary (n=1 centre)
and Estonia (n=1 centre).
3.2. Weaning commencement
In the participating centres, weaning commenced at age:< 17
weeks in 3% (n= 3/95), from 17 to 26weeks in 85% (n=81/95)
and > 26weeks of age in 12% (n=11/95). The main factors influ-
encing solids commencement were infant's age (n=85/95 centres) and
infants showing an interest in food (n=70/95). The first weaning
foods suggested by centres were low Phe vegetables (59%, n=56/95),
low Phe fruits (34%, n=32/95), low Phe cereal (6%, n= 6/95) and
low protein finger foods [1%, n=1/95].
Centres introduced Phe containing foods such as cereal, potato or
yoghurt to replace Phe from breast milk or standard infant formula at
infant age:< 17weeks in 1% (n= 1/95), from 17 to 26weeks in 51%
(n=48/95) and > 26weeks in 48% (n=46/95). Centres expressed a
preference for either allocating Phe containing foods by an exchange
system (52% of centres, n=49/95) or calculating the Phe content of
individual foods (48%, n= 46/95). Some centres commented how they
choose a system according to the preference and ability of an individual
family and so use both systems in their centres.
When centres used exchange systems to allocate Phe, different Phe
amounts were used to define one Phe exchange: between 10 and 25mg
of Phe (19% of centres, n=18/95), 50mg of Phe (31%, n=29/95), or
an unspecified amount (11%, n=10/95), with some centres using
more than one exchange system, which was determined by the Phe
concentration of foods.
Low protein milks (e.g. ProZero®, Sno-Pro® and Dalia®) given as a
drink or added to foods such as low protein cereal/desserts were in-
troduced:< 6months of age in 1% (n=1/95) of centres, 6–8months
in 19% (n=18/95), 9–12months in 23% (n=22/95) and >
12months in 57% (n=54/95).
Low protein bread was introduced by centres at:< 6months of age
in 3% (n=3/95), between 6 and 8months in 36% (n=34/95),
9–12months, 44% (n=42/95) and > 12months in 17% (n=16/95).
3.3. Weaning process: L-AA supplement
A second stage L-AA supplement containing a higher Phe-free amino
acid concentration than Phe-free infant formula was introduced by
centres at the following infant ages:< 26weeks, 9% (n=9/95);
26–36 weeks, 41% (n=39/95); 37–52 weeks, 13% (n=12/95);
and > 1y, 37% (n=35/95) [Fig. 1].
Over half of the centres (53%, n=50/95) recommended that a
second stage L-AA supplement was administered as a semi-solid (paste/
gel), 18% (n=17/95) as a concentrated drink, 19% (n=18/95) as a
non-concentrated drink and 11% (n= 10/95) gave a second stage
protein substitute via a different, non-specified method.
4. Discussion
This paper reports European health professionals' infant weaning
practices in PKU. The initial approaches to weaning are very similar,
with the majority of centres introducing solids between 17 and
26weeks of age commencing with low Phe fruit and vegetables. There
were different systems to allocate calculated Phe containing foods into
the diet, and although over half of the centres introduced a more
concentrated source of protein substitute from 6months, centres from
Southern Europe and Western Europe A (Portugal, Spain, Greece,
Turkey, Belgium, France and The Netherlands) delaying its introduction
until after the first year of age.
There is evidence in non-PKU healthy infants that early solid in-
troduction reduces breast milk volume and deferring weaning until
6 months of age is not associated with lower acceptance of solid foods
[2]. However, in PKU, the age of weaning may affect the acceptance of
a second stage protein substitute and any rejection of protein substitute
is associated with worsening of blood Phe control. Although the ideal
time to introduce solids in infant’s with PKU is not established, as
second stage protein substitute is often added in parallel with low Phe
food introduction, later food introduction may alter acceptance of
second stage protein substitute [11].
While dietary Phe (to replace Phe from breast milk or infant for-
mula) was added either in the form of an exchange system or by cal-
culating Phe intake of most foods, there was suggestion that dietary
practices were changing and were more flexible. Some centres in-
troduced lower Phe containing fruits and vegetables at weaning
without calculation which should benefit infants by improving infant
exposure to a wider range of tastes and textures. Over recent years the
system of allocating dietary Phe has provoked much discussion but
increasing evidence is supporting a ‘simple’ diet in PKU [12–14] and
there is no data to suggest that this is associated with loss of blood Phe
control. The European PKU Guidelines [15] supported a system where
Fig. 1. The age of introduction of a second stage protein substitute in each age
category by centres in different geographical regions.
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fruits and vegetables containing Phe ≤75mg/100 g are considered as
‘exchange free’ foods and thereby permitted without measurement
[16–18]. There is also evidence suggesting that there may be some over
restriction of prescribed dietary Phe below individual tolerance [19].
European countries using Phe exchange systems do not seem to have
worse metabolic control than centres that estimate all Phe intake [20].
In addition, Phe food analysis is associated with inaccuracy and pub-
lished figures of the Phe content of food are inconsistent [21]. Fur-
thermore, different definitions for the amount of Phe in one exchange
were used in our survey and future PKU guidelines should aim to
harmonize practice. It is essential patients receive standard information
from health professionals, especially when so much information is ac-
cessible through the internet and social media.
There is already a high burden for caregivers of children with PKU
with the extra time associated with managing the disorder [22,23],
which may lead to caregivers reducing working hours or even leaving
their jobs [23]. It has been reported in a UK survey that a median of
almost 2 h per week was spent weighing foods [23] using an exchange
system. It is likely that even more time will be necessary if Phe intake
from almost all food is measured, resulting in additional anxiety, al-
though it has been documented that many families do not sustain the
practice of weighing foods beyond early childhood [24].
This survey indicated low use of low protein special foods during
weaning. Generally, Northern European centres introduced these foods
earlier than other regions, which may be influenced by low protein food
availability and national prescription systems. Introduction of low
protein foods in the first year might be associated with better accep-
tance, but if caregivers must pay for them, they may consider that high
waste (common during weaning) does not justify their expense. In ad-
dition, caregivers are at an early stage in attaining their low protein
cooking skills, which may also limit infant exposure to low protein
special products. Delayed introduction and lack of exposure to their
textures or taste may lead to rejection but this needs further exploration
in PKU.
Second stage protein substitutes were recommended in various
forms according to geographical region. This could be related to
availability of protein substitutes in different countries. Almost two
thirds of centres introduced a second, more concentrated source of Phe-
free L-AA supplement by the time infants were aged one year. The
majority of centres from Southern Europe delayed its introduction until
after the first year of age but overall there was a change in practice from
an earlier multicentre study [5], which was associated with an even
later introduction of a concentrated protein substitute. A study ex-
amining feeding problems in PKU, showed that high volumes of Phe-
free liquid L-AA supplement (required if a concentrated protein sub-
stitute is not introduced during weaning) was associated with crying,
screaming, gagging and protein substitute rejection [25,26]. Practice
may be to add second stage protein substitute to a feeding bottle, and
although this may help to conceal its bitter taste and distinct smell, it
does not support good dental health or overall feeding development.
In a retrospective, longitudinal review over 15 years, Evans et al.
[11] showed that a semi-solid/spoonable L-AA supplement given from
20weeks was well tolerated, and any feeding problems encountered
were comparable to the problems observed in children without PKU. In
this study, there was a trend for children weaned before 17weeks of age
and those commencing weaning protein substitute late (> 26weeks of
age) to refuse a second stage, spoonable L-AA supplement at some
point. In our survey, only 9% of centres commenced a second stage
weaning L-AA supplement before 26weeks and 37% started only after
the first year of age. Prospective longitudinal studies are required to
compare the effect of earlier and late introduction of second stage
protein substitute with longer-term acceptance of L-AA supplements in
PKU.
This study had several limitations. It was a cross-sectional study
rather than prospective. The questionnaire was non-validated although
a pilot questionnaire was tested. Data was collected about general
health professional practice rather than individual prescriptions.
Therefore, this survey did not collect data about individual Phe toler-
ance or blood Phe control. Only one questionnaire was completed by
each PKU centre and it is possible that different professionals may have
had different approaches within the same centre.
5. Conclusions
Weaning strategies vary widely according to different European
regions. There is very little data about the definitive weaning process in
PKU and this survey gives useful information on how different health
professionals in treatment centres across Europe manage PKU. There is
also suggestion that weaning practices have changed compared with an
earlier survey. No reports are available assessing how different strate-
gies may influence adherence to the PKU diet and acceptance of Phe-
free L-AA supplement during childhood and later in life, so prospective
long-term studies are important. It is essential to define the most ac-
ceptable weaning strategy for infants associated with the least caregiver
burden and the best long term outcome in PKU.
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